With WuXi and Alnylam in tow, Vir enlists NIH as it tests various tools to fight the coronavirus scourge
George Scangos-led Vir Biotechnology has not only allied with Alnylam to mount a defense against the burgeoning coronavirus crisis, it has also joined forces with the NIH.
In the final days of February, investor enthusiasm flourished as Vir disclosed it had honed in on two antibodies that bind the spike protein of SARS-CoV-2, the virus behind Covid-19 — and unveiled a collaboration with WuXi Biologics for anti-SARS-CoV-2 antibodies. Last week, Vir announced it had expanded its existing collaboration with RNAi player Alnylam to include the development of an RNAi therapeutic targeting SARS-CoV-2.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
